Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout ...

A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

Editing DNA with the same ease as spell-checking a Word document is a scientific holy grail. It would allow debilitating and deadly genetic diseases to not only be treated, but cured. The US Food and ...

CRISPR Therapeutics (CRSP) on Saturday announced new results from a Phase 1 trial for CTX310, an in vivo gene editing therapy ...

“It’s something we need to pay attention to, especially as CRISPR expands to more diseases,” Sam Kulkarni, the CEO of CRISPR Therapeutics, which was not involved with either study, tells STAT News.

A single infusion of CRISPR Therapeutics' experimental gene therapy was safe and reduced levels of harmful LDL cholesterol ...

Crispr stock reversed lower Monday, while Intellia stock surged, on promising updates for their gene-editing efforts.

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Gene therapy has been on a roller-coaster ride since the first patient was treated 33 years ago. This slow-motion story took another turn this week after a panel of experts potentially set the stage ...